Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01786226 | Mifepristone to Treat Uterine Fibroids | terminated | Phase 2 / Phase 3 | 220 | Mediterranea Medica S. L.OTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT00702702 | Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 56 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids |
| terminated |
| Phase 3 |
| 77 |
| Repros Therapeutics Inc.INDUSTRY |
| 1 |
| Aug 21, 2014 |
| clinicaltrials |
| NCT00737282 | Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids | terminated | Phase 3 | 175 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00785356 | Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 8 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00853567 | Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 71 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01069120 | Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 27 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00350948 | Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer(ASSIST-5) | terminated | Phase 3 | 244 | TelikINDUSTRY | 4 | Nov 27, 2013 | clinicaltrials |
| NCT00085631 | Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer | terminated | Phase 3 | 101 | Mark DewhirstOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00566644 | Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome | terminated | Phase 3 | 600 | St George's, University of LondonOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00006096 | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva | terminated | Phase 3 | — | Gynecologic Oncology GroupNETWORK | 2 | Jun 10, 2013 | clinicaltrials |
| NCT00002819 | Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer | terminated | Phase 3 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00002976 | Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer | terminated | Phase 3 | 2,108 | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00016341 | Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer | terminated | Phase 3 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00054067 | Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix | terminated | Phase 3 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00332280 | Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo | terminated | Phase 2 / Phase 3 | 67 | Auron Healthcare GmbHINDUSTRY | 2 | Mar 20, 2013 | clinicaltrials |
| NCT00006356 | Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer | terminated | Phase 3 | 38 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00418574 | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients(MIMOSA) | terminated | Phase 2 / Phase 3 | 888 | Menarini GroupINDUSTRY | 9 | Nov 24, 2011 | clinicaltrials |
| NCT01363466 | Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer | terminated | Phase 3 | 61 | UNICANCEROTHER | 1 | Jun 1, 2011 | clinicaltrials |
| NCT00653952 | CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | terminated | Phase 3 | 220 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Apr 27, 2010 | clinicaltrials |
| NCT00050375 | Clinical Trial for Ovarian Cancer (OvaRex®) | terminated | Phase 3 | 354 | Unither PharmaceuticalsINDUSTRY | 1 | Dec 18, 2007 | clinicaltrials |
| NCT00047632 | Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer | terminated | Phase 3 | 847 | InterMuneINDUSTRY | 1 | Nov 1, 2007 | clinicaltrials |
| NCT00189371 | Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum | terminated | Phase 3 | 300 | AGO Study GroupOTHER | 1 | Sep 19, 2005 | clinicaltrials |
Data updated 23 days agoSource updated Sep 5, 2014source: clinicaltrials